




RealRate

PHARMACEUTICAL 2024

Matinas Biopharma Holdings Inc
Rank 125 of 309

MATINAS

BIOPHARMA



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Matinas Biopharma Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas Biopharma Holdings Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Matinas Biopharma Holdings Inc is the variable Net Income, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 249%, being 36% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	15,543
Cost of Goods Sold	0
Intangible Assets	4,353
Liabilities, Current	2,622
Liabilities, Non-Current	3,236
Other Assets	3,285
Other Compr. Net Income	603
Other Expenses	0
Other Liabilities	0
Other Net Income	824
Other Revenues	1,096
Property and Equipment	1,923
Research and Development	14,489
Selling, General and Administrative Expense	10,373

Output Variable	Value in 1000 USD
Assets	25,104
Liabilities	5,858
Expenses	24,862
Revenues	1,096
Stockholders Equity	19,246
Net Income	-22,942
Comprehensive Net Income	-22,640
BaseVar	29,174
ECR before Limited Liability	125%
Economic Capital Ratio	249%